Telix Pharmaceuticals Lim...

NASDAQ: TLX · Real-Time Price · USD
11.29
-0.61 (-5.13%)
At close: Aug 19, 2025, 3:59 PM
11.25
-0.35%
After-hours: Aug 19, 2025, 07:55 PM EDT

Telix Pharmaceuticals Income Statement

Financials in AUD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
783.21M 502.55M 160.1M 7.6M
Cost of Revenue
273.53M 188.16M 130.76M 37.36M
Gross Profit
509.68M 314.39M 29.34M -29.77M
Operating Income
82.13M 51.89M -73.18M -81.25M
Interest Income
10.86M 235K 1K 163K
Pretax Income
56.06M 3.09M -98.62M -99.04M
Net Income
49.92M 5.21M -104.08M -80.51M
Selling & General & Admin
232.86M 134.16M 87.1M 40.81M
Research & Development
194.64M 128.84M 57.86M 34.13M
Other Expenses
54K n/a 3.09M 23.55M
Operating Expenses
427.55M 263.27M 102.52M 51.48M
Interest Expense
21.46M 13.56M 406K 189K
Selling & Marketing Expenses
115.2M 54.87M 37.97M 5.89M
Cost & Expenses
701.08M 451.03M 233.28M 88.84M
Income Tax Expense
6.14M -2.12M 5.46M -18.53M
Shares Outstanding (Basic)
331.23M 319.18M 310.64M 282.21M
Shares Outstanding (Diluted)
345.19M 323.71M 310.64M 282.21M
EPS (Basic)
0.15 0.02 -0.34 -0.29
EPS (Diluted)
0.14 0.02 -0.34 -0.29
EBITDA
92.55M 22.97M -92.84M -70.07M
EBIT
92.55M 16.22M -98.22M -75.25M
Depreciation & Amortization
n/a 6.74M 5.38M 5.17M